Fri, Feb 27, 2015, 10:23 AM EST - U.S. Markets close in 5 hrs 37 mins


% | $
Quotes you view appear here for quick access.


camvest 23 posts  |  Last Activity: 16 hours ago Member since: Dec 28, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • 2 experiences I had at Walmart. I bought a pair of Corey running shoes there. A depression developed right under the ball of the foot that caused my sock to bunch up and become very uncomfortable. So I finally cut open the shoe to see why it was so uncomfortable, not being able to wear it anymore. In the top of the sole material right below where the ball of the foot goes there was a manufactured sideways cut taken out of the material. The lining of the shoe was not sufficient to support my foot without having material beneath so that is where the depression developed and that ruined the entire shoe. The same thing is happening with a pair of Brahma boots I bought there so I'm just waiting for warmer weather to take them apart, but I suspect its the same problem. In my mind, the idea of mass production is to make a better product at a lower price. A third pair of high top insulated boots I bought at the same time had so much stiff insulation stuffed in an unyielding ridge around the top of the boot, it chafed my legs badly and I had to cut the tops of the boots off to wear them. Fortunately I bought the boots at a low enough price so next time I can get a better pair of boots somewhere else. But this looks like planned obsolescence. In other words the product is sold relatively inexpensively to induce you to buy it and to throw it away and not take it back if there is a problem and the manufacturer knows you will get limited use out of the product so eventually you will have to buy another pair. There is a problem with the design of the shoes and somewhere in the Walmart organization there is a problem with whoever is doing the buying, because when you buy product in the massive amounts that Walmart does it should be high quality and inexpensive. In the Walmart of today, it's just cheap, but that's not enough to sell me when the product is unusable.

  • Europe approves Western world’s first stem-cell therapy for rare eye condition
    Good article, could mean approval for Ocata therapies not far off.

  • Don't know if anyone posted this yet, but it might be good news if it happens:
    1/27/2015 Benitec considering partnerships for multiple programs,
    CEO says
    Proprietary Intelligence
    Story Benitec (OTC:BTEBY, ASX:BLT), the Sydney, Australia-based
    company focused on DNA-directed RNAi therapies, has been
    attracting partnership interest over the last 12 months, said
    CEO Peter French.
    “We are having discussions about many of our pipeline
    programs with multiple pharma companies,” French said. He
    declined to disclose which companies have been involved in
    partnership discussions with Benitec. The company is not
    interested in a sale and plans to build a pipeline of programs,
    he said.
    The company’s gene silencing technology, ddRNAI, could
    provide a “single shot cure” for a variety of diseases and
    medical conditions including Hepatitis C, Hepatitis B, drug
    resistant lung cancer, wet AMD (Age-related Macular
    Degeneration) and the orphan genetic disease OPMD
    (oculopharyngeal muscular dystrophy), French said.
    When asked if Benitec had been working with an investment
    bank, French said it had worked with Maxim Investment Bank
    in New York last February to raise AUD 30m from healthcare
    institutional investors and Maxim had also assisted with
    partnership discussions.
    French said the fundraisingn gave the company increased
    visibility in the US and Benitec is now considering whether it
    wants to have a stronger US presence. The company currently
    has a laboratory in San Francisco, but it may also consider
    adding a US-based headquarters and moving its US stock
    listing from the OTC board to one of the major exchanges, he
    said. The company is looking “at a range” of investment banks to assist with the potential exchange move but is willing to hold discussions with additional banks outside of this group, French said. Benitec’s market cap on the ASX is approximately AUD 112m. Benitec’s ddRNAI platform technology introduces a small DNA sequence directly into a cell’s nucleus where it silences unwanted or disease-causing genes which can result in long-lasting, positive therapeutic outcomes. Drugs created from the company’s platform technology have fewer side effects, have a more specific delivery of the therapy, and can have multiple therapies in one molecule, French said. The company’s lead drug candidate, TT-034, is undergoing a Phase I/IIa trial for the treatment of Hepatitis C. This is an “open label dose escalation study” so the company will be reporting results on an ongoing basis, French said. Benitec expects to be reporting data to the FDA in the first half of 2016. TT-034 would be able to eliminate the usual long course of treatment for Hepatitis C, French said, noting that patients often have compliance issues with multiple-dose therapies which can hinder positive outcomes. Benitec now has sufficient funding for the next few years, French said, noting Benitec has a cash balance of approximately AUD 30m. The company has a cash burn of about AUD 9m per year and Australia’s R&D tax incentive program provides the company with “a longer cash runway”, French said. The February 2014 capital raise will enable the company to take TT-034 through the Phase IIb trial, he said. Benitec has in-house programs in the areas of Hepatitis C, Hepatitis B, drug resistant lung cancer, wet AMD and OPMD. It already has licensing agreements with Calimmune for HIV/AIDS, with Regen BioPharma (OTC: RGBP) for cancer vaccines, with uniQure (NASDAQ: QURE) for Huntington’s Disease, with Genable for Retinitis Pigmentosa, and with Circuit for neuropathic pain. The company’s legal advisers are FAL in Australia and DLA
    Piper in the US. by Ilene

  • Reply to

    Benitec news

    by bigbangchester Feb 4, 2015 11:38 PM
    camvest camvest Feb 6, 2015 4:50 PM Flag

    Dr. Chiplin would probably have sold a greater percentage of his shares if he was concerned about the company's progress. The dollar amount of the shares he sold ($45,500) probably represents normal profit-taking. Everybody has expenses. Dr. Chiplin also has options for another 400,000 shares expiring in 2016 at $1.25. Nice, I see Benitec's share price and volume is up today.

  • There is a good video on youtube if you search the caption above. Stephen Minger is the head of GE's Life Sciences division. Somewhere in the video (which is all worth watching) he mentions Calimmune and the silencing they are doing to close the cell surface pathways that allow HIV to enter immune cells. It seems he is aware of just about everything that is happening in regenerative medicine. Is it possible Benitec could be a partner with GE in developing ddRNAi? Looks pretty interesting because one of the things he mentioned is that GE is developing automated testing of protein toxicity at various doses and this would be critical in order to develop and test possible side effects throughout the body of the proteins produced or silenced by synthetic DNA. Also according to Dr. Minger could eliminate the need for in vitro and animal testing and tremendously reduce the cost of new drug development.

  • camvest camvest Jan 28, 2015 9:18 PM Flag


    I am looking at the "Fiscal Summary" page in the "Market Snapshot" done by Shaw Stockbroking for the ASX, found at the ASX site. I see that the Shaw report is projecting a big increase in operating revenues for Benitec from 1.2 million in 2015 to 60.1 million in 2016. I contacted Shaw and Carl Stubbings to shed some light on this projection and I didn't hear back any relevant information from either one of them. You see to know a lot about Benitec so have you seen the market snapshot and do you know what is the cause of that projected increase. I am concerned they are going to do further dilution but if they sell additional shares that would not be operating revenue increase would it? Just wondering why no one seems to have an answer.

  • camvest camvest Jan 27, 2015 2:58 PM Flag

    I went to the link and just saw that video for he first time so that's a great find. Thanks. They're talking about Ocata, of course, and a lot of potential investors new to the subject should find that video very interesting.

    Sentiment: Strong Buy

  • Reply to

    Colonial Trust Advisors picked up shares

    by camvest Jan 26, 2015 9:51 PM
    camvest camvest Jan 26, 2015 11:34 PM Flag

    Look at Major Holders

  • I see that Colonial Trust Advisors has started a position in Ocata. They have apparently been around for over 100 years and Ocata is joining the company of Microsoft, Coca Cola, PepsiCo, Union Pacific, Walt Disney, and Duke Energy among others. They have about 140 substantial companies in their portfolio according to NASDAQ.

  • camvest camvest Jan 26, 2015 9:36 PM Flag

    Excellent find, George.

  • camvest camvest Jan 24, 2015 4:59 PM Flag

    What are you talking about as you drone on? The facts and independent research shows that glyphosate affects health and the genetic modification of plants potentiates horizontal gene transfer both with negative repercussions to health. Why are you babbling on about global warming and speculating on non-confirmable correlations between various beliefs. Jut stick to the facts and maybe you'll begin to realize that human health is more important than quarterly profits.

  • Search "" and "Deterioration of Public Health"

  • Reply to

    Insider Transaction

    by mfirth555 Jan 5, 2015 5:10 PM
    camvest camvest Jan 5, 2015 9:36 PM Flag

    Helps to dilute share price, too which makes it easier for investors to buy shares of this growing company.

  • Reply to

    Insider Transaction

    by mfirth555 Jan 5, 2015 5:10 PM
    camvest camvest Jan 5, 2015 9:33 PM Flag


    It's always easier to ask than to read. I'll give u a thumbs up on this.

  • Reply to

    Patent Application 13905526

    by theresnobeachhere Dec 22, 2014 9:12 PM
    camvest camvest Dec 22, 2014 10:32 PM Flag

    Have to agree beach, the IP continues to pile up will lead to increasing trend.

    Sentiment: Strong Buy

  • It appears there are options to acquire shares as low #$%$325 till February 2015

  • camvest camvest Dec 18, 2014 11:04 PM Flag

    Not many cops go to work looking to shoot somebody because it's easier for them to get paid just for doing their job and hoping that nothing goes wrong. The lawyer for the Browns described this as case where the kid got killed for stealing cigars, which is a complete fabrication. That's what leads me to believe the cop is telling the truth plus the testimony of the majority of African American witnesses on the grand jury who more than likely would have wanted to indict this cop if he did something wrong.

  • shows listing as OTC

  • camvest by camvest Dec 12, 2014 7:18 PM Flag

    For BNIKF

  • Reply to

    The truth about glyphosate

    by camvest Dec 10, 2014 9:55 PM
    camvest camvest Dec 11, 2014 8:02 PM Flag

    wow, that's hilarious

6.97+0.17(+2.50%)Nov 13 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.